Carcinoma “evanescente” de la próstata

Studer, 1993, Radical prostatectomy or watch and wait?, Eur Urol, 24, 24, 10.1159/000474384

Berenguer, 1996, “Screening” del cáncer de próstata: un problema no resuelto, Actas Urol Esp, 20, 768

Vaillancourt, 1996, Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: a randomized study, Am J Surg Pathol, 20, 86, 10.1097/00000478-199601000-00010

Goldstein, 1995, Minimal or no cancer in radical prostatectomy specimens: report of 13 cases of the “vanishing cancer phenomenon”, Am J Surg Pathol, 19, 1002, 10.1097/00000478-199509000-00003

Partin, 1989, Morphometric measurement of tumor volume and per cent of gland involvement as predictors of pathological stage in clinical stage B prostate cancer, J Urol, 141, 341, 10.1016/S0022-5347(17)40761-0

Sakr, 1993, The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients, J Urol, 150, 379, 10.1016/S0022-5347(17)35487-3

Iczkowski, 1997, Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies, Am J Surg Pathol, 21, 1489, 10.1097/00000478-199712000-00012

Digiuseppe, 1997, Increasing incidence of minimal residual cancer in radical prostatectomy specimens, Am J Surg Pathol, 21, 174, 10.1097/00000478-199702000-00006

Pummer, 1994, Hormonal pretreatment does not affect the final pathologic stage in locally advanced prostate cancer, Urology Symposium, 44, 38, 10.1016/S0090-4295(94)80242-4

Soloway, 1995, Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer, J Urol, 154, 424, 10.1016/S0022-5347(01)67067-8

Poppel, 1995, Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial, J Urol, 154, 429, 10.1097/00005392-199508000-00027

Armas, 1994, Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma, Am J Surg Pathol, 18, 979, 10.1097/00000478-199410000-00002

Mai, 1996, Absence of serum prostate-specific antigen and loss of tissue immunoreactive prostatic markers in advanced prostatic adenocarcinoma after hormonal therapy: a report of two cases, Hum Pathol, 27, 1377, 10.1016/S0046-8177(96)90354-8

Blackwell, 1994, Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage:the influence of prostate specific antigen cancer density, J Urol, 151, 1565, 10.1016/S0022-5347(17)35303-X

Troxel, 1994, Problem areas in pathology practice, uncovered by a review of malpractice claims, Am J Surg Pathol, 18, 821, 10.1097/00000478-199408000-00009

Stamey, 1993, Localized prostate cancer: relationship of tumor volume to clinical significance for treatment of prostate cancer, Cancer, 71, 933, 10.1002/1097-0142(19930201)71:3+<933::AID-CNCR2820711408>3.0.CO;2-L

Epstein, 1994, Pathological and clinical findings to predict tumor extent of non-palpable (stage T1c) prostate cancer, JAMA, 271, 368, 10.1001/jama.1994.03510290050036

Digiuseppe, 1997, Minimal residual prostate cancer, Am J Surg Pathol, 21, 1525, 10.1097/00000478-199712000-00021

Chan, 1997, Follow-up of atypical prostate needle biopsies (Abstract, Mod Pathol, 10, 71